intrODuctiOn Tuberculosis (TB) is prevailing as a burning public health problem worldwide, and pulmonary TB is a major focus of concern. In 2015, 10.4 million new TB cases had been recorded. According to the World Health Organization (WHO), India accounts for 23% of the total global TB burden. [1] The incidence rate of TB is 217 per one lakh population per year and about 4.8 lakhs people die due to TB annually in India. India also has the highest burden of multidrug resistant-TB (MDR-TB) and the rate is 2.5% among new TB cases and 16% among previously treated Purpose: The Revised National Tuberculosis Control Programme (RNTCP) is now introducing daily fixed-dose regimen instead of Directly Observed Treatment, Short Course (DOTS) regimen for treatment of drug-sensitive tuberculosis (TB) in India. It would be beneficial to understand the drawbacks, barriers and advantages of the existing system for better implementation of new policy. Our study was aimed to evaluate the current microbiological status of new microbiologically confirmed pulmonary TB patients who have successfully completed intermittent DOTS regimen within last 2 years and also to find the economic barriers faced by beneficiaries to avail DOTS treatment. Materials and Methods: We included patients who had completed CAT 1 DOTS regimen within the last 2 years. The patients were interviewed. Sputum sample was collected for microscopy and cartridge-based nucleic acid amplification test. Results: All patients were adhered to intermittent DOTS therapy, and sputum conversion rate was 83%. Minor gastrointestinal side effects were experienced by 60% of cases and 87% consumed drugs under supervision. On microbiological examination, 10% of the study population was found to be positive for TB and they all were rifampicin sensitive. Those who had completed treatment within 1 year with no clinical symptoms re-appeared after treatment. Conclusion: Till date, RNTCP does not follow up the patients for any period of time after successful completion of treatment. Through the present study, we could find relapse cases in 10% of the previously treated non-symptomatic patients. These unnoticed relapse cases have potential to spread TB and increase disease burden of country. Thus, we can conclude that RNTCP has to follow up the patients after successful treatment to determine whether they relapse. It is needed for the success of programme and control of the disease in the country.
TB cases. [1] To combat high TB burden and to revitalise TB control activities, the internationally recommended Directly Observed Treatment, Short Course (DOTS) strategy was adopted by the Revised National Tuberculosis Control Programme (RNTCP) in India in 1997. Till now, the RNTCP has been following thrice-weekly regimen for treatment of drug-sensitive pulmonary TB. [2] Due to the high relapse rate and increasing drug resistance with intermittent therapy, daily treatment with fixed-dose combination, especially in intensive phase (IP), has been advised in WHO, 2010 Tuberculosis Treatment Guideline. [3] The programme is now introducing daily fixed-dose regimen for treatment of drug-sensitive TB as per Technical and Operational Guidelines for Tuberculosis Control in India 2016. It will start in the entire country for HIV-TB co-infection and paediatric patients and in 104 districts for all TB patients. [2] Such a shift from intermittent to a daily regimen has wide-ranging aftermath for public health systems and logistical challenges will be faced. It would be beneficial to understand the drawbacks, barriers and advantages of the existing system for better implementation of the new policy. Against this background, we have conducted a study in a tertiary healthcare centre of eastern India, to assess clinical and microbiological status after completion of the DOTS regimen for microbiologically confirmed pulmonary TB to identify recurrence of TB, on ESI beneficiary patients, with low monthly income. We also documented the hindrance faced by those previously treated patients to complete full course.
matErials anD mEtHODs
An observational, cross-sectional epidemiological study was conducted in the Department of Microbiology, ESI-Post-graduate Institute of Medical Science and Research, Kolkata. The study population was patients who had been diagnosed as microbiologically confirmed pulmonary TB cases, either new or relapse, and also had completed thrice-weekly DOTS regimen within last 2 years were included after informed consent.
Exclusion criteria
a. Age <12 years b. HIV sero-positive c. Seriously ill TB patients d. Treatment failure TB cases e. Patients with known anti-tubercular drug resistance f. Pulmonary TB treated patients who were not willing to participate in the study.
The study was performed following the steps described below:
Retrospective data collection from laboratory records
From the RNTCP sputum microscopy record register, the details of the sputum smear positive patients of last 2 years (2015-2016) were collected. The details include name, age, sex, contact number, address, sputum microscopy result and date of diagnosis.
Communication with the patients through phone calls
Patients were communicated over phone and explained the purpose and procedure of the study. Those who were willing to take part in this study were asked about their history of TB, treatment history and current health status. Among them, who had completed thrice-weekly DOTS regimen were requested to visit the Microbiology Department. They were advised to bring one morning sample, RNTCP record card and prescriptions.
Meeting with the patients
After getting informed written consent from the patients, they were assessed in three steps by interviewing, collection of data and microbiological sampling.
Interview of the patients
A pre-designed open-ended questionnaire was used to interview the patients. Demographic data of the study population were collected regarding parameters such as age, sex, religion, residence, occupation, literacy status and socioeconomic status.
Socioeconomic status of the case population was assessed by the BG Prasad scale of 2016.
The patients were asked about difficulties to attend the DOTS centre thrice weekly, expenditure for travelling, their loss of wages, social taboo for TB, adverse effects of treatment and reappearance of any suggestive clinical symptoms in detail.
Data collection from the Revised National Tuberculosis Control Programme identity card
Data regarding category of treatment, treatment duration, time of sputum conversion, completion of treatment and status of patients at the end of treatment were collected from the individual RNTCP identity card.
Sample collection
Patients were given specimen containers with the instructions to provide a quality specimen. Two samples were collected on the spot under supervision and the other was collected early in the morning. One spot and morning sputum sample were sent for sputum microscopy and one sputum sample was sent for molecular testing by cartridge-based-nucleic acid amplification test (CB-NAAT).
Microbiological assessment of the sputum smear by fluorescence staining
The sputum containers were labelled properly and send to the laboratory. Smears were prepared from mucopurulent part, fixed and stained using fluorescence techniques following RNTCP guideline. Examination, reporting and grading of positive smears were also done following 'RNTCP Manual for Sputum Smear Fluorescence Microscopy'. [2] 
Molecular assessment by cartridge-based-nucleic acid amplification test
Collected sputum samples were transferred to the district TB centre, 15/1, Gobinda Khatik Road (Tangra) Kolkata -70046, to perform the test.
Liquid culture of cartridge-based-nucleic acid amplification test-positive sputum samples
Fresh sputum samples were from the patients who were found positive by CB-NAAT. Sputum culture was done in liquid culture system BacT/ALERT ® 3D system (bioMerieux Inc., Durham, NC, USA).
Feedback
The patients were informed about the report of fluorescence microscopy and CB-NAAT over phone. Patients, who were found positive by sputum smear positive and/or CB-NAAT, were counselled and referred to the nearest RNTCP centre. Repeat sputum samples were collected for repeat CB-NAAT test and then liquid culture and drug sensitivity testing as per RNTCP protocol.
rEsults
A total of 2801 suspected pulmonary TB patients were tested by sputum microscopy during 2015 and 2016 as per RNTCP record registers. Out of them, 126 patients were detected acid-fast bacilli (AFB) positive. Details of those sputum smear positive patients (n = 126) were collected from the register. Among them, 88 patients (70%) could be communicated through phone calls [ Figure 1 ].
On the basis of inclusion and exclusion criteria, thirty patients who had completed Category I intermittent DOTS regimen due to pulmonary TB were selected for the study. The minimum interval period of 2 months between completion of treatment and sampling was maintained.
Age varied from 21 years to 67 years with a median age of 40 years. No paediatric TB case was present in our study. Majority (30%) of the patients belonged to the age group of 21-40 years. Males predominated (83.34%) in the study population. Patients were almost equally distributed in urban (53%) and rural areas (47%). Most of the populations (36.67%) were factory workers and all the females (23.34%) were homemakers.
Among our cases, no patient was defaulted from the DOTS regimen [ Figure 2 ]. During the treatment, follow-up sputum examinations were done at the end of 2 months in the CAT I patients. The sputum conversion rate was 83.34% at the end of IP. Rest of the patients (16.67%) were declared sputum negative at the end of continuous phase (CP). Nearly 23.34% of patients reported to have symptoms after completion of IP. Among those patients, 71.4% (5 of 7) had haemoptysis and 28.6% (2 of 7) had cough and chest pain. Gastrointestinal disturbances (60%) were noted in the initial IP as a side effect of chemotherapy. Supervision was not done during consumption of drugs in IP for 13.34% of patients, neither by DOTS provider nor a family member.
Sputum conversion rate among the supervised group was 81% and among patients without supervisor, it was 100% [ Table 1 ]. Four patients among five who were failed sputum microscopy conversion at the end of IP did not complain of re-appearance of suggestive clinical symptoms.
As described in Table 2 , 53.34% of the cases had to travel between 1 and 5 km of distance to DOTS centre and 56.67% had to spend an average 40 min for to and fro journey to the RNTCP centre. Public transports such as bus and auto rickshaw were used by 46.67% patients, whereas 50% patients managed to travel by themselves. One patient was bedridden and drugs were supplied by the DOTS provider at his home. A majority of 53.34% did not need to spend money for their journey, whereas 33.34% patients spent ₹1-30 for their journey. In majority of the cases (53.4%), daily income was not affected, whereas 16.6% patients had to loss their part of daily wages to attend centre thrice weekly. Nearly 30% of the study population had to sacrifice their full income of the day due to the time lost in the journey to avail therapy from DOTS.
On microbiological examination, 10% (n = 3) of the study population found to be positive for TB [ Figure 3 ]. The detection rate by microscopy was 3.3% and by CB-NAAT 10%. Rifampicin resistance was not detected in any of the samples. All the three CB-NAAT positive cases were confirmed by liquid culture for presence of viable bacilli. The time interval between completion of DOTS regimen and study sputum collection was >6-12 months for all positive cases [ Figure 4 ].
The patient 1, a young factory worker, completed regimen without any adverse reaction before 8 months under supervision [ Table 3 ]. Patients 2 and 3 were aged more than 50 years and experienced nausea, vomiting and pain abdomen during IP. Only patient 3 had asthma as associated disease and regularly used steroid inhaler and also took the medicines unobserved throughout the course due to ill-health.
DiscussiOn
TB is the largest killer among communicable diseases in the young, reproductive adult human population (15-49 years age group). [1] TB is preventable and completely curable disease and can be treated with various regimens. Both daily and intermittent regimens can be used for the treatment of TB. The main principle of DOTS is that a directly supervised therapy, which ensures compliance and a regular treatment with low cost drugs and prevents drug resistance. The case detection is done by sputum smear microscopy. Hence, the main focus is to stop the chain of the transmission to decrease the new TB cases and the development of multidrug-resistant TB. Unfortunately, even with introduction of DOTS regimen in India, for more than a decade, TB is still one of the leading causes of mortality (two persons in every 3 min, nearly 1000/day). The number of sputum smear positive cases is 41 per lakh of population. WHO revised the situation; it published a guideline in 2010 and recommended daily treatment as the preferred drug regimen in treatment for all patients with TB to improve the outcomes of patients. [4] Hence, RNTCP felt the need to shift from the current intermittent DOTS to a daily regimen.
TB affects the young adults most commonly. [1] In our study, most of the affected patients were in the age group of 21-40 years. A previous study also had shown similar predominance of young, working reproductive age among TB patients. [4] Sputum negetive 27 (90%) In our study, we found 83.34% sputum conversion rate at the end of IP, which is similar to the findings of another study from Kolkata. [4] One meta-analysis showed the primary success rate of intermittent regimen was 88% without any significant difference with daily dosing. [5] No case of our study population discontinued treatment and the default rate was 0%. Though earlier studies from India showed variable default rates (2%-20%) in intermittent group, very low default rate was documented in daily regimen during meta-analysis. [4] [5] [6] As we collected retrospective data in our study, the defaulter cases might be missed due to lack of communication. Minor adverse effects, such as nausea and vomiting, were noted in 60% of patients during the initial IP of the chemotherapy. Serious side effects reported in previous studies were hepatitis, skin rashes and gastritis. [4] Nearly 86.6% of patients consumed drugs during IP under supervision, but CP was not supervised in any patients. Sputum conversion was comparable between supervised (81%) and unsupervised groups (100%). This finding concurs with that reported by other study. [5] In the present study, 53.34% patients had to travel more than 1 km distance to DOTS centre from their home and 46.67% patients had to avail public transport. 30% of the study population had to sacrifice their full income of the day to avail therapy from providers. A qualitative study from south India reported that due to long distance and inconvenient timings of DOTS centres, patients had to struggle to reach them on time and the cost of transport was the reason most frequently given for non-compliance. [7] Another study done in different states of India and documented response of health providers and found transportation, loss of wage for accessing DOTS institute are major hindrances for patients to complete regimen on time. They also suggested 'Family DOTS' concept in a daily regimen that DOTS can be provided by any identified/ responsible family member such as spouse, parent/s, sibling etc., to ensure better adherence. [8] Our study population was previously treated pulmonary TB cases. When they were examined microbiologically for TB, 10% (3/30) patients turned out to be positive. All three cases were positive by CB-NAAT test, whereas only one case was positive for AFB by sputum fluorescence microscopy. The CB-NAAT positive cases were also positive by liquid culture. Therefore, the relapse rate (newly termed as recurrent TB) in the present study is 10% among new pulmonary TB cases who were declared to be treated successfully (either cured or completed treatment). This finding is corroborates with previous studies which documented relapses close to 10% or more in patients who received intermittent treatment compared with 5% among patients who received drugs daily. [9, 10] When analysing multiple international studies, relapse rates were found to be 7% among intermittent group. [7] Though CB-NAAT detected more cases than sputum microscopy in this study, it cannot replace culture, 'the gold standard treatment monitoring tool' due to its low specificity. But till now CB-NAAT has been evaluated as treatment response monitor on patients undergoing treatment for TB, whereas our study population had completed treatment at least before 6 months. [11] Though no relapse case was harbouring MDR-TB as rifampin resistance not detected by CB-NAAT in the present study, any previously treated TB case is under definition of presumptive Drug Resistant TB. Resistance is high (16%) among previously treated cases in India as per WHO. [1] It was also found that relapse cases were contributing to more than 60% of the patients receiving re-treatment and as many as 40% of all patients with MDR disease. [7] A retrospective study from Nagpur highlighted high proportion of MDR-TB among the relapse cases (47%). [10] Emphasised use of CB-NAAT in the diagnostic algorithm by current RNTCP guideline will be helpful to detect relapse cases and multidrug resistance simultaneously. [2] This integrated molecular technique is more accurate and rapid than microscopy for diagnosing TB.
In our study, the three relapse cases were 30-60 years of male patients, who completed DOTS therapy within 1 year without a history of re-appearance any symptoms during the course of treatment and sputum conversion at the end of IP. Three of them were smokers, whereas one was under treatment with steroid inhaler for asthma. Two of them used to visit DOTS centre thrice weekly and consumed drugs under supervision, but one patient failed to travel due to weakness. The patient's son used to collect medicines and he consumed them at home unattended. Patients had to walk for minimum 20 min to reach the centre and sacrificed their partial day's wages (average ₹110/-). The majority (68.5%) of relapse occurred in the 1 st year of completion of treatment as reported by other study. [12] Smoking, being male, presence of concomitant disease, drug irregularity and initial drug resistance were listed as potential contributors to recurrent TB. [12] Long travelling distances, burden of transport cost, income loss to make centre visit during working hours are important hindrance of DOTS as reported by Yellappa et al. [7] cOnclusiOn In India, under RNTCP, the percentage of smear-positive re-treatment cases out of all smear-positive cases is 24%. [2] The causes of re-treatment include relapse, failure, and default in treatment. RNTCP does not follow up the patients for any period of time after successful completion of treatment to determine whether they relapse. Given the high cost of treatment for each patient under RNTCP and the potential chance of spread of disease from these patients, it is crucial to find out the reasons behind relapse. Monitoring the timely response to treatment in such cases has significant role in the success of the programme and control of the disease in our country.
When the patients were followed up after treatment completion in our study, 10% patients were found microbiologically sputum positive again without any suggestive symptoms. These unnoticed relapse cases are potential to spread TB and increase disease burden of the country. As drug resistance is not the reason behind relapse in these cases, so the efficacy of therapeutic regimen is questionable. CB-NAAT, which has already been included in RNTCP protocol as diagnostic tool, could also have the potential to become an efficient tool than microscopy detecting relapse cases during long-term follow-up. The problem of travelling and loss of income faced by the patients to avail the facility of free supervised treatment indicates the barrier of institution based intermittent therapy. Scope of choosing a family member as a supervisor/DOTS provider in the new guideline will facilitate to overcome these programmatic challenges.
